These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

722 related articles for article (PubMed ID: 28541636)

  • 21. Impact of increased utilization of neoadjuvant chemotherapy on survival in patients with advanced ovarian cancer: experience from a comprehensive cancer center.
    Lee YJ; Chung YS; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT
    J Gynecol Oncol; 2018 Jul; 29(4):e63. PubMed ID: 29770632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).
    Chi DS; Musa F; Dao F; Zivanovic O; Sonoda Y; Leitao MM; Levine DA; Gardner GJ; Abu-Rustum NR; Barakat RR
    Gynecol Oncol; 2012 Jan; 124(1):10-4. PubMed ID: 21917306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy of systematic lymph node dissection in advanced epithelial ovarian cancer during interval debulking surgery performed after neoadjuvant chemotherapy.
    Eoh KJ; Yoon JW; Lee I; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    J Surg Oncol; 2017 Sep; 116(3):329-336. PubMed ID: 28542980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival After Primary Debulking Surgery Compared With Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A National Cancer Database Study.
    Seagle BL; Graves S; Strohl AE; Shahabi S
    Int J Gynecol Cancer; 2017 Oct; 27(8):1610-1618. PubMed ID: 28763362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness.
    da Costa Miranda V; de Souza Fêde ÂB; Dos Anjos CH; da Silva JR; Sanchez FB; da Silva Bessa LR; de Paula Carvalho J; Filho EA; de Freitas D; Del Pilar Estevez Diz M
    Gynecol Oncol; 2014 Feb; 132(2):287-91. PubMed ID: 24333355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery.
    Stoeckle E; Bourdarias L; Guyon F; Croce S; Brouste V; Thomas L; Floquet A
    Ann Surg Oncol; 2014 Feb; 21(2):629-36. PubMed ID: 24052318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.
    Zhang J; Liu N; Zhang A; Bao X
    J Obstet Gynaecol Res; 2018 Sep; 44(9):1808-1816. PubMed ID: 30019801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
    Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
    Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer.
    Luo Y; Lee M; Kim HS; Chung HH; Song YS
    Medicine (Baltimore); 2016 Sep; 95(36):e4797. PubMed ID: 27603388
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patterns of Recurrence and Clinical Outcome of Patients With Stage IIIC to Stage IV Epithelial Ovarian Cancer in Complete Response After Primary Debulking Surgery Plus Chemotherapy or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery: An Italian Multicenter Retrospective Study.
    Gadducci A; Cosio S; Zizioli V; Notaro S; Tana R; Panattoni A; Sartori E
    Int J Gynecol Cancer; 2017 Jan; 27(1):28-36. PubMed ID: 27870700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer.
    Xu X; Deng F; Lv M; Chen X
    Arch Gynecol Obstet; 2017 Feb; 295(2):451-458. PubMed ID: 27913927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pattern of recurrence after interval cytoreductive surgery and HIPEC following neoadjuvant chemotherapy in primary advanced stage IIIC/IVA epithelial ovarian cancer.
    Sinukumar S; Damodaran D; Ray M; Mehta S; Paul L; Bhatt A
    Eur J Surg Oncol; 2021 Jun; 47(6):1427-1433. PubMed ID: 33509612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Platinum-Based Neoadjuvant Chemotherapy versus Primary Surgery in Ovarian Carcinoma International Federation of Gynecology and Obstetrics Stages IIIc and IV: A Systematic Review and Meta-Analysis.
    Xiao Y; Xie S; Zhang N; Wang J; Lv C; Guo J; Yang Q
    Gynecol Obstet Invest; 2018; 83(3):209-219. PubMed ID: 29402804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
    Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
    J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
    Munoz-Zuluaga CA; Sardi A; Sittig M; Gushchin V; King MC; Nieroda C; Lopez-Ramirez F; Diaz-Montes TP
    Int J Surg Oncol; 2020; 2020():1467403. PubMed ID: 33381312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A Single-Institution Experience and a Review of the Literature.
    Loizzi V; Leone L; Camporeale A; Resta L; Selvaggi L; Cicinelli E; Cormio G
    Oncology; 2016; 91(4):211-216. PubMed ID: 27487241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does the Number of Neoadjuvant Chemotherapy Cycles before Interval Debulking Surgery Influence Survival in Advanced Ovarian Cancer?
    Akladios C; Baldauf JJ; Marchal F; Hummel M; Rebstock LE; Kurtz JE; Petit T; Afors K; Mathelin C; Lecointre L; Schrot-Sanyan S
    Oncology; 2016; 91(6):331-340. PubMed ID: 27784027
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter?
    Markauskas A; Mogensen O; dePont Christensen R; Jensen PT
    Int J Gynecol Cancer; 2014 Oct; 24(8):1420-8. PubMed ID: 25180461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary debulking surgery versus neo-adjuvant chemotherapy in stage III/IV ovarian cancer: Comparison of perioperative morbidity and survival data in Pakistani women.
    Chishti U; Aziz AB
    J Pak Med Assoc; 2015 Mar; 65(3):306-9. PubMed ID: 25933567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Centralisation of epithelial ovarian cancer surgery: results on survival from a peripheral teaching hospital.
    van Vliet MM; Schreuder HW; Pasker-de Jong PC; Duk MJ
    Eur J Obstet Gynecol Reprod Biol; 2015 Sep; 192():72-8. PubMed ID: 26177496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.